Joy Bessenger
Directeur Financier/CFO chez TRELLUS HEALTH PLC
Profil
Ms. Joy Bessenger is a Chief Financial Officer at Trellus Health Plc.
Ms. Bessenger was previously employed as a Senior Vice President-Corporate Strategy by IMV, Inc. and a Director-Investor Relations by deCODE genetics, Inc. She received her undergraduate degree from the University of South Florida.
Postes actifs de Joy Bessenger
| Sociétés | Poste | Début |
|---|---|---|
| TRELLUS HEALTH PLC | Directeur Financier/CFO | 18/09/2023 |
Anciens postes connus de Joy Bessenger
| Sociétés | Poste | Fin |
|---|---|---|
| IMV INC. | Investor Relations Contact | 11/06/2022 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Public Communications Contact | - |
Formation de Joy Bessenger
| University of South Florida | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IMV INC. | Health Technology |
| TRELLUS HEALTH PLC | Technology Services |
| Entreprise privées | 1 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
